Dear All (with thanks to Kevin for leading on this newsletter and with a wonkish / long-read alert on this email … settle in for the ride!), Great news from TEAM UK! As of 12 August, the UK Subscription Program is no longer a pilot but is fully operational with an initial application deadline of
Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list… CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds,
Dear All, Just published in AAC is WHO’s updated review of the global preclinical pipeline. Here are the links you need to follow today’s discussion: The new WHO review: Gigante et al. “Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps”, https://doi.org/10.1128/aac.00535-24, AAC 2024. An excellent AAC podcast (overview webpage; YouTube video) discussing the WHO review. In
23 July 2024 addenda x 2: Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to
Dear All, Yow! Led by David Paterson, ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases) is a research group launched March 2023 as a network of more than 30 hospitals across Asia. The exciting news is that ADVANCE-ID have just announced that they are seeking a novel antimicrobial agent vs. MDR Gram-negatives that could be advanced in the clinic
Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals” (press release, report itself), its key message of “Researchers Are Leaving the AMR Field – Even as the Threat Rapidly Grows” is illustrated vividly by the report’s graphics. I’m going
Dear All (wonk-ish note alert and also with particular thanks as always to Kevin Outterson for helping to refine this newsletter): Sparked at least in part by the innovation metrics in recent pipeline analyses (specifically, the ideas of No Cross-Resistance, New Chemical Class, New Target, and New Mechanism of Action) used in the 2018 pipeline
Dear All, Last fall, the team at ATMF (Access to Medicine Foundation) released the 3rd update to the AMR Benchmark series and Damiano de Felice was a guest author for a newsletter about the findings. That report offered a wealth of granular data, in-depth analyses and revealing graphs about what pharmaceutical companies in the global antibiotic and
Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial
Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,